Biotech
Ginkgo Bioworks
Ginkgo Bioworks raises $350M Series E at $4.9B valuation
Boston, MASeptember 15, 20201 min read
Total Raised
$350M
Valuation
$4.9B
Latest Round
Series E
Employees
600+
Ginkgo Bioworks: Series E Funding Round
Ginkgo Bioworks has successfully raised $350M in Series E funding, reaching a valuation of $4.9B.
Company Overview
Synthetic biology and organism engineering
Funding Details
The Series E round was led by Baillie Gifford, with participation from ARK Investment Management.
Company Information
- Headquarters: Boston, MA
- Founded: 2008
- Employees: 600+
- Category: Biotech
Investment
Ginkgo Bioworks plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Baillie Gifford: Verified investor in Series E
- ARK Investment Management: Verified investor in Series E
Company Info
Headquarters
Boston, MA
Founded
2008
Team Size
600+
Last Round
$350M(Sep 2020)
Investors (2)
B
Baillie GiffordLeadLead Investor
Verified investor in Series E
A
ARK Investment ManagementInvestor
Verified investor in Series E
Share
Related Reports
Biotech
AusperBio
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free